Deep im­pact: Drugs to watch in Q3 — PBM analy­sis

In re­cent years, the lure of or­phan, rare dis­eases has tempt­ed biotech and phar­ma­ceu­ti­cal com­pa­nies to re­serve a sig­nif­i­cant tranche of re­sources to de­vel­op treat­ments — which usu­al­ly car­ry pre­mi­um price-tags — to ad­dress the lu­cra­tive mar­ket. But the meat of earn­ings, in re­cent decades, has come from treat­ing chron­ic con­di­tions by prof­it­ing from vol­ume-dri­ven sales.

Op­tum, a US phar­ma­cy ben­e­fit man­ag­er owned by health in­sur­er Unit­ed­Health, has nar­rowed down a short­list of drugs to watch out for in the third quar­ter, as man­u­fac­tur­ers fo­cus on en­gi­neer­ing clev­er­er, more po­tent ap­proach­es to tack­le dis­eases that im­pact large swathes of the glob­al pop­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER